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1197-12 Cerebral Hyperperfusion and Intracranlal Hemorrhage 
Following Internal Carotid Artery Stenting 
Alex Abou-Chebl, Joel Reginelli, Debabreta Mukherjse, Deapek Bbat, Christopher 
Bajzer, Jay Yadav, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: The rate of hyperperfusion hemorrhage following carotid endarterectomy 
is 0.3-1.5%. Little is known about the frequency and risk factors for intracerebral hemor- 
rhage and the cerebral hyperperfusion syndrome following internal carotid artery stenting 
(CAS). 
Methods: We reviewed the prospective computerized atabase of all CAS procedures 
performed in the pedpheral interventional laboratory to identify patients who developed 
intracerebral hemorrhage. 
Results: A total of 205 consecutive patients with a mean stenosis of 83.4% _+12.4% 
underwent CAS over a three-year period. There were three (1.5%) cases of intracerebral 
hemorrhage, one immediate and two delayed (mean 4 _+1.4 days). All three patients had 
correction of a severe (mean 96% +5.2%) internal carotid artery stanosis with a concom- 
itant >80% stenosis or occlusion of the contralateral carotid artery. Atl three patients had 
hypertension preoperatively and the two patients with delayed hemorrhage developed 
hypertension postoperatively. Aspidn, clopidogrel, and heperin were given to all three 
patients, additionally one received eptifibatide and one received abciximab during the 
procedure. Two of the three patients died and one recovered with persistent neurological 
deficits. 
Conclusion: The cerebral hyperperfusion syndrome occurs infrequently following CAS 
but is a cause of significant morbidity and mortality when it does occur. Patients with 
severe, bilateral internal carotid artery stenosis and perioperative hypertension may be at 
particular isk. Vigilant postoperative monitoring and blood pressure control, in-hospital 
as well as after discharge, may be critical preventative measures. The role of antiplatelet 
and antithrombotic agents in the pathogenesis of hyparparfusion hemorrhage is unclear. 
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1198-1 Sonodynamlc Therapy Reduced Neolntimal Hyperplaeia 
After Stenting in Rabbit lilac Artery 
Koh Arakawa, Kousuke Hagisewa, Hiroyuki Kuseno, Satoru Yoneyama. Akira Kudta, 
Tunenod Arai, Makoto Kikuchi, Shin-ichirou Umemura, Iseo Sakata, Fumitaka Ohsuzu, 
National Defense Medical College, Tokorozawa, Japan. 
Background:ln-stent restenosis remains a pivotal problem after coronary and peripheral 
stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the 
activation of soncohemical sensitizers by ultrasound. PAD-S31 is known to be a water- 
soluble chlorin derivative sonochemical sensitizer. We assessed the efficacy of sonody- 
namic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model. 
Methods:Stents were implanted in the lilac arteries of 16 rabbits. Thirty-two stented arter- 
ies were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD- 
$31 groups. One hour after the intravenous administration of PAD-S31 of 25mg/kg, ultra- 
sound energy (1 MHz, 0.3W/cm2) was delivered transdermally to the sonodynamic ther- 
apy group. At 28 days, all stant sites were analyzed morphometrically. Results:The size 
of the intimal cross sectional area was smaller in the sonodynamic therapy group than in 
the control, ultrasound, and PAD-S31 groups (0.31±0.07 versus 1.38±0.47, 1.66±0.71, 
and 1.61±0.42 mm2, p<0.05). The ratio of the intimal and media cross sectional area 
was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD- 
$31 groups (0.71±0.22 versus 2.53±1.39, 2.48±0.60, and 3.45±1.42 mm2, p<0.05). The 
percent area stenosis was also significantly smaller in the sonodynamic therapy group 
than in the control, ultrasound, and PAD-S31 groups (23±7 versus 58±11, 53±14, and 
65±9 %, p<0.05). 
Conclusions:Sonodynamic therapy with PAD-S31 is considered to be a feasible treat- 
ment modality for non-invasively inhibiting neointimal hyperptasia in a rabbit iliac stent 
mode 
1198-2 Local Motexafin Lutetium Delivery With Subsequent 
Photoangioplasty Reduces Macrophagee and Atheroma 
Burden In a Rabbit Poetballoon Injury Model 
Kathryn W. Woodburn, Motovas Havasa, Paul Ycok, Alan C. Yeung, Pharmacyc/ics, 
Sunnyva/e, Ca/ifornia, Stanford University, Stanford, Ca/ifomia. 
Background: Motaxafin lutetium (MLu, Antdn ® Injection) is a phototherapeutic agent 
that selectively accumulates in atbaromatous plaque where it can be activated by far-red 
light. In this study, we assessed the feasibility and impact of local MLu administration with 
subsequent endovasoular illumination on the intima/media ratio and macrophage burden 
in a rabbit post-balloon injury model. Methods: New Zealand white rabbits (n=20) were 
fed a 1% cholesterol diet. After 2-3 weeks, bilateral ilac artery lesions were induced by 
balloon denudation, followed by continued feeding of the high cholesterol diet for a fur- 
ther 5-6 weeks. A local drug delivery catheter (3mm, Dispatch ®, Scimed) was introduced 
into the specified lilac artery to deliver 2.2 ml volumes of MLu (0.5 or 2.0 mg) or vehicle 
(5% mannitol). Photoactivation with endovascularly delivered light (photoangioplasty) 
was performed 15 minutes after sensitizer delivery (781 Joules/cm F at 830 mW/cmF). 
Two weeks post treatment, vessels were harvested and hematoxylin and eosin (H&E) 
and RAM 11 (macrophages) staining was performed. Results: Local administration of 2.0 
mg MLu and subsequent photoactivation led to a significantly lower infimal/media ratio 
compared with those animals receiving drug alone (1.44±0.17SEM versus 2.01±0.28, 
P=0.006). Quantitative planimetric analysis using RAM11 positive cells revealed signifi- 
cant reduction of macrophages in treated lesions in the 0.5 (6.74+1.50 versus 
15.06±1.92%, P<0.001) and 2.0 mg MLu (7.46+1.73 versus 15.06il.92%, P=0.001) 
phototherapy groups, compared with animals receiving only light treatment. Conclu- 
sions: Photoactivation of MLu within atheroma, after local deliver'/resulted in a signifi- 
cant decrease in macrophagea and a small decrease in atheroma burden. These 
findings have implications for a possible effect of MLu photoangiopleaty on plaque 
regression and stabilization. 
1198-3 Estrogen Reduces Neointime Formation Independent of 
INOS Expression in Mouse Carotid Ligetion Model of 
Vascular Injury 
Todd Tolbert, Philippe Bouchard, Suzanne Oparil, University of Alabama at Birmingham, 
Birmingham, A/abama. 
Background: Estrogen is vasoprotactive in animal models of vascular injury, yet the 
mechanisms involved are incompletely understood. Many lines of evidence indicate that 
inducible nitric oxide synthase (iNOS) plays a role in neointima formation after arterial 
injury and that 17~-estradiol (E2) modulates iNOS expression. This study tested the 
hypothesis that E 2 reduces neointima formation after vascular injury via a mechanism 
that is dependent on modulation of iNOS expression. 
Methods: Male and female wild type (iNOS+/+) mice and mica with homozygous dele- 
tion of iNOS (iNOS-/-) were studied intact (INT) or following ovarisotomy (OVX) and 
implantation of E 2 or vehicle (V). Mice were randomized to 8 groups based on gender, 
iNOS status, OVX, and treatment with E 2 or V (n=5-8 per group). Mice were sacrificed 28 
days after carotid ligation, and injured vessels were examined for cross-sectional neoint- 
imal areas. Results are expressed as means ± SEM. 
Results: There was a marked sexual dimorphism in neointima formation in both the 
iNOS +/+ mice and the iNOS -/- mica. iNOS +/+ INT females had a > 90% reduction in 
neointima formation compared to iNOS +/+males (0.17±0.03x104 pm 2 vs 2.88±0.41x104 
lim2; p<O.05), and iNOS -/- INT females had a 65% reduction in neoinfima formation 
compared to iNOS -/- males (0.42±0.10x104 pm 2 vs 1:20±0.28x104 ~m2; p<0.05). The 
sexually dimorphic response was attenuated by OVX and restored by E 2 replacement in 
both iNOS +/+ and iNOS -/- mice. Female iNOS +/+ OVX + E 2 mice had an 82% reduc- 
tion in neointima formation compared to female iNOS +/+ OVX + V mica (0.34±0.13x104 
lim 2 vs 1.94_+0.49x104 p.m2; p<0.05), and female iNOS -/- OVX + E 2 mice had a 70% 
reduction in neointima formation compared to iNOS -/- OVX + V (0.32:K).04x104 ~m 2 vs 
1.07_+0.19x104 lim2; p<0.O5). 
Conclusions: These results demonstrate that the vasoprotactive ffects of E 2 following 
vascular injury are, at least in part, independent of iNOS expression. 
1198-4 Intracoronary Administrat ion of Acetyl-'ryrosinyI-Valyl- 
AlanyI-AspertyI-Chlore-Methylketone (Ac-WAD-cmk)  
Reduces Neointimal Hyperplaeia After Stontlng of the 
Porcine Coronary Artery 
Mariann Gvonovosi, Wolfgang Sparker, Ursula Windberger, Michael Gottseuner-Wolf, 
Paul Wexberg, Diana Bonderman, Irene Lang, Peter Ferdinandy, Stafan Madovits, 
Dietmar Glogar, Division of Cardiology, University of Vienna Medics/Center, Vienna, 
Austria, Institute for Biomedica/ Research, Vienna, Austria. 
Background. The irreversible caspase-1 inhibitor acetyl-tyrosinyl-valyl-alanyl-sspertyl- 
chloro-methylketona (Ac-YVAD-cmk) inhibits apoptosis and proinflammatory cytokine 
release. In contrast to apoptosis inhibition, the chloromethylketon chain of Ac-YVAD-cmk 
increases smooth muscle cell apoptosis through eleatase inhibition. The aim of the 
present study was to reduce neointimal proliferation after coronary stant implantation 
using Ac-YVAD-cmk. Methods. After general anaesthesia, domestic pigs received intrac- 
oronary infusion of 50 mg Ac-YVAD-cmk (dissolved in 1 ml dimathylsulfoxid/DMSO/and 
59 ml phosphate buffer/PBS/, infusion rate 6ml/min) into the left coronary artery (group 
1, n=10), while 8 animals served as untreated controls (group 2) and 6 further pigs as 
vehicle controls (DMSO+PBS) (group 3). One coronary stent was then implanted in the 
left anterior descending or circumflex coronary artery. After 4 weeks, control angiography 
and intravascular ultrasound (IVUS) were performed. IVUS parameters were measured 
using computer-assisted 3D analysis system. Results. Ac-YVAD-cmk reduced in-stent 
neointimal volume (29.1±12.5 vs 80.5±24.9 and 67.4±22.3mm3, p<0.005) and maximal 
area stenosis (38.6±8.0 vs 71.0¢6.4 and 67.0±9.9%, p<0.001) assessed by IVUS in 
group 1 vs groups 2 and 3, but did not influence vessel remodeling (maximal vessel area 
12.4±3.3 vs 13.5±2.1 and 12.3±2.7mm3, nonsignificant). Smaller maximal neointimal 
thickness (0.38±0.19 vs 0.94±0.37 and O.97-z0.44mm, p<0.01 ) and decreased maximal 
neointimal area (1.73±1.53 vs 3.66±1.54 and 4.03±0.86mm2, p<0.01 ) assessed by his- 
tology (computerized planimetry) were found in pigs in group 1 vs groups 2 and 3. IVUS 
results (maximal neointimal area and neointimal thickness) correlated significantly with 
histological data (r=0.774, p<0.001 and r=0.699, p<0.001, respectively). Injury score did 
not differ significantly between the groups. Conclusions. Our data indicate that caspase- 
1 inhibitor Ac-YVAD-cmk reduces in-stent neointimal proliferation. IVUS allows a quanti- 
tative 3D analysis of experimental neointimal proliferation and vessel remodeling and is 
able to guide targeted histological analysis. 
